Deal Library / Pharma BD Deal Intelligence

Bristol-Myers Squibb Company — Pharma Deals

The Pharma Closeout tracks 50 deals, $218.4B in disclosed deal value, 30 with a post-close Outcome Score for Bristol-Myers Squibb Company.

Median Critic Score: 75  ·  Median Outcome Score: 48

Best outcome: Bristol-Myers Squibb Company / Medarex Inc. (92)  ·  Weakest outcome: Bristol-Myers Squibb Company / Inhibitex Inc. (8)

All 50 deals

• Bristol-Myers Squibb Company / Medarex Inc. — 2009 · $2.4B · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / Celgene Corporation — 2019 · $74.0B · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / Karuna Therapeutics — 2023 · $14.0B · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / MyoKardia Inc. — 2020 · $13.1B · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. — 2011 · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / SystImmune Inc. — 2023 · $8.4B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Turning Point Therapeutics Inc. — 2022 · $4.1B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Prime Medicine Inc. — 2024 · $3.5B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / RayzeBio Inc. — 2023 · $4.1B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Mirati Therapeutics — 2023 · $4.8B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Evotec SE — 2023 · $4.0B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / BioArctic AB — 2024 · $1.4B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / ImClone Systems Incorporated — 2001 · $2.0B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Dragonfly Therapeutics Inc. — 2020 · $475M · Mixed — partial payoff, real shortfalls.
• Bristol-Myers Squibb Company / DuPont Pharmaceuticals Company — 2001 · $7.8B · Mixed — partial payoff, real shortfalls.
• Bristol-Myers Squibb Company / Eisai Co., Ltd. — 2021 · $3.1B · Mixed — partial payoff, real shortfalls.
• Bristol-Myers Squibb Company / Agenus Inc. — 2017 · $1.6B · Mixed — partial payoff, real shortfalls.
• Bristol-Myers Squibb Company / Amylin Pharmaceuticals — 2012 · $5.3B · Underwhelmed — fell short of the thesis.
• Bristol-Myers Squibb Company / IFM Therapeutics, LLC — 2017 · $2.3B · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Padlock Therapeutics, Inc. — 2016 · $600M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Nektar Therapeutics — 2018 · $3.6B · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Cormorant Pharmaceuticals AB — 2016 · $520M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Flexus Biosciences, Inc. — 2015 · $1.2B · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Five Prime Therapeutics, Inc. — 2014 · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Exelixis, Inc. (TGR5 + ROR programs) — 2010 · $565M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Kosan Biosciences Incorporated — 2008 · $190M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / ZymoGenetics, Inc. — 2010 · $885M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Cardioxyl Pharmaceuticals, Inc. — 2015 · $2.1B · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Exelixis, Inc. — 2008 · $240M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Inhibitex Inc. — 2012 · $2.5B · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Jiangsu Hengrui Pharmaceuticals Co., Ltd. — 2026 · $15.2B
• Bristol-Myers Squibb Company / BioNTech SE — 2025 · $11.1B
• Bristol-Myers Squibb Company / 2seventy bio, Inc. — 2025 · $286M
• Bristol-Myers Squibb Company / Orbital Therapeutics, Inc. — 2025 · $1.5B
• Bristol-Myers Squibb Company / Repertoire Immune Medicines Inc. — 2024 · $1.9B
• Bristol-Myers Squibb Company / Tubulis GmbH — 2023 · $1.0B
• Bristol-Myers Squibb Company / Century Therapeutics Inc. — 2022 · $3.1B
• Bristol-Myers Squibb Company / Immatics N.V. — 2022 · $770M
• Bristol-Myers Squibb Company / Agenus Inc. — 2021 · $1.6B
• Bristol-Myers Squibb Company / Immatics N.V. — 2021 · $920M
• Bristol-Myers Squibb Company / Repare Therapeutics Inc. — 2020 · $3.1B
• Bristol-Myers Squibb Company / Anokion SA / Kanyos Bio Inc. — 2019 · $1.3B
• Bristol-Myers Squibb Company / Halozyme Therapeutics, Inc. — 2017 · $1.9B
• Bristol-Myers Squibb Company / Promedior, Inc. — 2015 · $1.2B
• Bristol-Myers Squibb Company / Bavarian Nordic A/S (PROSTVAC program) — 2015 · $975M
• Bristol-Myers Squibb Company / Five Prime Therapeutics, Inc. (CSF1R antibody program) — 2015 · $1.7B
• Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. — 2014
• Bristol-Myers Squibb Company / CytomX Therapeutics, Inc. — 2014 · $1.2B
• Bristol-Myers Squibb Company / Allergan, Inc. (EHT/AGN 0001 license) — 2010 · $413M
• Bristol-Myers Squibb Company / Adnexus Therapeutics Inc. — 2007 · $430M

← Deal Library  ·  Interactive search  ·  How we score deals